


Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis



Web Annex A. Declarations of interest for the
Guideline Development Group and external peer reviewers



World Health
Organization

Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis

**Web Annex A. Declarations of interest for the
Guideline Development Group and external peer reviewers**

Some rights reserved. This work is available under the [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/) licence.

Suggested citation. Web Annex A. Declarations of interest for the Guideline Development Group and external peer reviewers. In: Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP). Geneva: World Health Organization; 2025. <https://doi.org/10.2471/B09483>

This publication forms part of the WHO document entitled *Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP)*. It is being made publicly available for transparency purposes and information, in accordance with the *WHO handbook for guideline development*, 2nd edition (2014).



Declarations of interest for the Guideline Development Group and external peer reviewers

Guideline Development Group members (*n*=19)

Gender identity	Percentage
Cis men	37%
Cis women	58%
Nonbinary	5%

Region	Percentage
African	31%
Americas	24%
European	15%
Eastern Mediterranean	10%
South-East Asia	10%
Western Pacific	10%

Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products	Conflicts management plan
Nadia Badran, SIDC, Lebanon	—	—	—	—	—	—	—	Full participation
Alma Griselda De León Calderón, ITPC=LATCA, Guatemala	—	—	—	—	—	—	—	Full participation
Tatiana Deshko, Alliance for Public Health, Ukraine	—	—	—	—	—	—	—	Full participation
Julie Fox, King's College London, United Kingdom	—	—	—	—	—	—	—	Full participation



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products	Conflicts management plan
Le Minh Giang, Hanoi Medical University, Viet Nam	—	2a) Research support. Grant support from National Institutes of Health, USA	—	—	—	—	—	Full participation
Chilufya Kasanda Hampongo, Treatment and Advocacy Literacy Campaign, Zambia	—	—	—	—	—	—	—	Full participation
Mehdi Karkouri, Association de la lutte contre le sida, Morocco	—	—	—	—	—	—	—	Full participation
Kelika Konda, Impacta, Peru	—	2a) Research support. Gilead has donated oral TDF/FTC (PrEP) to Impacta, a research group that I work with part time. I was not involved in the study design or execution, nor have I received any payments from Gilead.	—	—	—	—	—	Full participation



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products	Conflicts management plan
Nikolay Lunchenkov, University of Munich, Germany	—	—	—	—	—	—	—	Full participation
Idah Moyo, Ministry of Health, Zimbabwe	—	—	—	—	—	—	—	Full participation
Sikhulile Moyo, Botswana Harvard Institute, Botswana	—	—	—	—	—	—	—	Full participation
Misael Munoz, Inspira Cambio, Mexico	—	—	—	—	—	—	—	Full participation
Kenneth Mwehonge, Coalition for Health Promotion and Social Development (HEPS)-Uganda, Uganda	—	—	—	—	—	—	—	Full participation
Estelle Piwovar Manning, independent consultant, USA	—	—	—	—	—	—	—	Full participation



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products	Conflicts management plan
Danvic Rosadino, Love Yourself, Philippines	—	—	—	—	—	—	—	Full participation
Yashwinder Singh, Humsfar Trust, India	—	—	—	—	—	—	—	Full participation
Hasina Subedar, National Department of Health, South Africa	—	—	—	—	—	—	—	Full participation
Ni Ni Tun, Medical Action Myanmar, Myanmar	—	—	—	—	—	—	—	Full participation
Rebecca Zash, Botswana Harvard Institute, USA	—	—	—	—	—	—	—	Full participation



External Peer Review Group (n=20)

Conflicts management: The steering group assessed comments for validity on a case-by-case basis, in the context of the reviewer’s conflicts of interest.

Gender identity	Percentage
Cis men	50%
Cis women	50%

Region	Percentage
African	20%
Americas	30%
European	25%
Eastern Mediterranean	10%
South-East Asia	5%
Western Pacific	10%

Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products
Max Appenroth, Diversity Factory, Germany	1b) Keynote about inclusive language in research, MSD Sharp & Dohme GmbH, 595€, 2023 1b) External consultant, MSD Sharp & Dohme GmbH, 2025. I was asked to be a consultant, but I have not received any money yet, nor has it been discussed what the amount of remuneration will be.	—	—	—	—	—	—



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products
Ngauv Bora, National Centre for HIV/AIDS Dermatology and STDs, Cambodia	—	—	—	—	—	—	—
Erika Castellanos, Global Action for Trans Equality (GATE), Netherlands	—	—	—	—	—	—	—
Elizabeth Corbett, London School of Hygiene and Tropical Medicine, United Kingdom	—	2a) Research grants to my institution, Unitaid and Wellcome Trust, employer (research institute), US\$ 1 million, past interest 2b) Travel to five different meetings, PSI and Liverpool School of Tropical Medicine covered costs only, unsure of amount, current interest	—	—	—	—	—
Brenda Crabtree Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico	—	1b) Non-monetary support, Gilead	—	—	—	—	—



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products
Ines Dourado, University of Bahia, Brazil	—	—	—	—	—	—	—
Kim Green, PATH, Switzerland	—	2a) Research support, PATH, US\$ 2000, current interest	—	—	—	—	—
Karin Hatzold, PSI, South Africa	—	—	—	—	—	—	—
Artur Kalichman, Ministry of Health, Brazil	—	—	—	—	—	—	—
Othoman Mellouk, International Treatment Preparedness Coalition, Morocco	—	—	—	—	—	—	—
Lloyd Mulenga, Ministry of Health, Zambia	—	2a) I received a research grant in 2019 from Gilead on TAF use for PrEP in cis-gender women.	—	—	—	—	—
Urvi Parikh, US Centers for Disease Control and Prevention and University of Pittsburgh, USA	—	—	—	—	—	—	—
Jason Reed, Jhpiego, USA	—	—	—	—	—	—	—



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products
Jeanne Sibiude, Agence Nationale de Recherche sur la SIDA – Maladies infectieuses émergentes (ANRS–MIE), France	—	—	—	—	—	—	—
Christian Stillson, Clinton Health Access Initiative, USA	—	—	—	—	—	—	—
Linda Stranix-Chibanda, University of Zimbabwe and International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPACT), Zimbabwe	—	2a) Research support, HIV prevention trials network (NIAID), organization, past, 5% effort for five years, below US\$ 10 000/year, none	—	—	—	—	—
Nicky Sebastian Suwandi, Asia-Pacific Coalition on Male Sexual Health (APCOM), Thailand	—	—	—	—	—	—	—
Joseph Tucker, UNC Project China, China	—	—	—	—	—	—	—



Name and affiliation	1. Consulting and technical advisory boards	2. Research support	3. Investments and business interests	4. Intellectual property	5. Public statements and positions	6. Additional information	7. Tobacco products
Francois Venter, Ezintsha, South Africa	—	2a) Research support, Bill & Melinda Gates Foundation, my organization, grant for access to PrEP in private pharmacies, current 2b) Non-monetary support, ViiV, my organization, donation of cabotegravir for an implementation study, current	—	—	—	—	—
Rita Wahab, MENA Rosa, Lebanon	—	—	—	—	—	—	—

**Department of Global HIV, Hepatitis
and Sexually Transmitted Infections
Programmes**

World Health Organization
Avenue Appia 20
1211 Geneva
Switzerland

www.who.int